Blood Tests and HLA-B27: What They Can and Cannot Tell You
Understand inflammatory markers, HLA-B27, RF and anti-CCP, and the difference between diagnostic and treatment-safety blood tests.
All chapters in this collection
Understanding the diagnosis
- 1. Peripheral SpA, Undifferentiated SpA and a Working Diagnosis
- 2. Joints, Entheses and Dactylitis: Understanding the Peripheral Pattern
- 3. How the Diagnosis Is Built
- 4. New Symptoms: What Changes the Picture and When Not to Wait
Tests and imaging
- 5. Blood Tests and HLA-B27: What They Can and Cannot Tell You
- 6. Ultrasound, MRI, X-ray and Joint Aspiration: Choosing the Right Test
Treatment decisions
- 7. What Are We Actually Trying to Improve?
- 8. NSAIDs, Local Treatment and Conventional DMARDs
- 9. When Targeted Therapy Enters the Discussion
Daily life and follow-up
- 10. Movement, Feet, Hands, Work and Everyday Load
- 11. How Do We Know Treatment Is Working?
- 12. Pregnancy, Infection, Surgery and Other Medical Conditions
When the picture changes
- 13. Why the Diagnosis May Change
- 14. When Pain, Examination, Blood Tests and Imaging Disagree
- 15. Remission, Treatment Reduction and Long-Term Outlook
Research and future care
A blood test is most useful when you know the question it was ordered to answer. Some tests help evaluate inflammation; some change the likelihood of a diagnosis; others check whether treatment is safe. An abnormal result in one category does not automatically answer the questions in the others.
CRP and ESR: signals in context
C-reactive protein, or CRP, and the erythrocyte sedimentation rate, or ESR, can support an assessment of inflammation. They do not identify which joint or organ is responsible. Infection and other illnesses can also raise them, and ESR can be influenced by factors unrelated to current joint inflammation.
Normal results do not exclude SpA. For some people, the markers have never tracked their joint findings well. For others, a change alongside swelling and function is useful. Your own pattern over time matters more than treating every number outside a reference range as a separate diagnosis.
If a marker rises unexpectedly, the appropriate response is to investigate the context. Increasing immune-suppressing treatment solely because a number increased could miss an infection or another explanation.
HLA-B27: inherited information, not an activity score
HLA-B27 is an inherited immune-system marker. It is associated with several SpA-related conditions, but healthy people can carry it. A positive result can strengthen a compatible clinical assessment; it does not prove that current heel pain or a swollen joint is caused by SpA.
A negative result does not exclude the diagnosis. The usefulness of the result depends on the symptoms, examination, family background and other evidence. It is not a measure of severity, and it does not become positive when disease flares or negative when treatment works.
Because inherited status does not ordinarily change, repeated testing is usually unnecessary once a reliable result is available. Ask the reason if it is ordered again; sometimes the earlier result or assay needs clarification. Relatives should not assume that your result means they have the same disease.
RF and anti-CCP: questions about another pattern
Rheumatoid factor and anti-CCP antibodies can help assess rheumatoid arthritis when the clinical pattern makes that diagnosis relevant. A negative result does not automatically establish SpA, just as a positive result needs interpretation rather than replacing the examination.
The clinician considers the type and distribution of joint swelling, symptom evolution and other findings together. A low-level unexpected result may carry a different meaning from a strongly positive result in a matching clinical setting. Discuss the complete assessment rather than comparing a single value with someone else’s report.
Blood counts, liver and kidney tests
A complete blood count can identify anemia and changes in white cells or platelets. Chemistry tests may assess kidney function, liver-related abnormalities or other problems. These tests can investigate symptoms or provide a baseline before treatment.
During treatment, they may be scheduled even when you feel well because some adverse effects initially cause no symptoms. A safety result is not the same as a disease-activity result: normal liver tests do not mean arthritis is inactive, and a medication-related abnormality does not necessarily mean the underlying diagnosis was wrong.
Why more testing is not always better
A large untargeted panel increases the chance of finding an abnormal result that does not explain your illness. That can lead to anxiety and further testing without improving the decision. A focused test is selected because a plausible result would change the next step.
This does not mean that unexplained symptoms should be dismissed. It means that investigation should follow the clinical question. Persistent diarrhea, an acutely swollen joint and preparation for a biologic may each require different tests even in the same person.
Reading a result with your clinician
Ask what the test measures, why it was ordered, whether the result fits the examination and what happens next. Check units and the laboratory’s reference range before comparing reports. Bring the actual dated result when possible; “my inflammation test was high” leaves out information that may matter.
A useful follow-up plan identifies which tests need repetition and why. It also explains what should prompt earlier contact, rather than asking you to interpret every change alone. For symptoms and blood results that disagree, see how discordant findings are assessed. For information that blood cannot provide, see imaging and joint aspiration.